TO DETERMINE THE SURVIVAL OF PATIENTS WITH BRAIN METASTASES AFTER PALLIATIVE WHOLE-BRAIN RADIOTHERAPY – AN EXPERIENCE FROM A SINGLE INSTITUTE
DOI:
https://doi.org/10.55519/JAMC-04-12111Keywords:
Brain Neoplasm; Radiotherapy; Survival; Quality of LifeAbstract
Background: Brain metastases are a common complication of cancer and approximately 20% of cancer patients develop them over time. Presently palliative whole-brain radiotherapy is used as a palliative treatment for brain metastases because of its cost-effectiveness and easy availability, especially in patients with multiple metastases who are not candidates for surgery or Stereotactic radiosurgery. This study aims to determine the survival in patients who have received palliative whole-brain radiotherapy for brain metastases and to evaluate some of the prognostic factors determining survival in patients with brain metastases. Methods: It was a cross-sectional study conducted in Shaukat Khanum Memorial Cancer Hospital and Research Centre and all the patients with brain metastases who had completed palliative whole-brain radiotherapy between July 2015 and July 2020 were included. Data was retrospectively collected and analyzed using SPSS 21.0. Overall survival was calculated using the Kaplan-Meier method, taking into consideration the period from the date of diagnosis of brain metastases until death or to the date of last follow-up, whichever was applicable. p-value of <0.05 was regarded as statistically significant. Results: Almost half (45%) of the brain metastases were secondary to breast cancer followed by lung and genitourinary cancers at 16.3% and 15.5% respectively. The median overall survival was lowest in breast carcinoma patients at 5 months followed by lung carcinoma at 7 months. The median overall survival was 5 months in patients having extracranial disease as compared to 12 months in those having no extracranial disease or those in whom the disease status was unknown. Conclusions: Our study revealed that the most common tumour to metastasize to the brain was breast cancer. The younger age group had a poorer prognosis because most of them had breast cancer with triple-negative disease. Controlled extracranial disease significantly prolonged overall survival in patients with brain metastases.References
Sacks P, Rahman M. Epidemiology of Brain Metastases. Neurosurg Clin N Am 2020;31(4):481–8.
Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, et al. Brain metastases. Nat Rev Dis Primers 2019;5(1):5.
Liu Q, Tong X, Wang J. Management of brain metastases: history and the present. Chin Neurosurg J 2019;5:1.
Noh T, Walbert T. Brain metastasis: clinical manifestations, symptom management, and palliative care. Handb Clin Neurol 2018;149:75–88.
Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96(1):103–14.
Nagtegaal SHJ, Hulsbergen AFC, van Dorst EBL, Kavouridis VK, Jessurun CAC, Broekman MLD, et al. Age, pathology and CA-125 are prognostic factors for survival in patients with brain metastases from gynaecological tumours. Clin Transl Radiat Oncol 2020;24:11–5.
Moravan MJ, Fecci PE, Anders CK, Clarke JM, Salama AKS, Adamson JD, et al. Current multidisciplinary management of brain metastases. Cancer 2020;126(7):1390–406.
Zhou C, Xia Y, Huang P, Guan L, Shen X, Hao D, et al. Fractionated Stereotactic Radiation Therapy Using Volumetric Modulated Arc Therapy in Patients with Solitary Brain Metastases. Biomed Res Int 2020;2020:6342057.
Trifiletti DM, Ballman KV, Brown PD, Anderson SK, Carrero XW, Cerhan JH, et al. Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3). J Radiat Oncol Biol Phys 2020;106(2):255–60.
Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2012;2012(4):CD003869.
Park K, Bae GH, Kim WK, Yoo CJ, Park CW, Kim SK, et al. Radiotherapy for brain metastasis and long-term survival. Sci Rep 2021;11(1):8046.
Suteu P, Fekete Z, Todor N, Nagy V. Survival and quality of life after whole brain radiotherapy with 3D conformal boost in the treatment of brain metastases. Med Pharm Rep 2019;92(1):43–51.
Saito EY, Viani GA, Ferrigno R, Nakamura RA, Novaes PE, Pellizzon CA, et al. Whole brain radiation therapy in management of brain metastasis: results and prognostic factors. Radiat Oncol 2006;1:20.
Reali A, Allis S, Girardi A, Verna R, Bianco L, Redda MG. Is Karnofsky Performance Status Correlate with Better Overall Survival in Palliative Conformal Whole Brain Radiotherapy? Our Experience. Indian J Palliat Care 2015;21(3):311–6.
Datsenko PV, Gerasimov VA, Belikova AA. [Short-term survival prediction scale in patients with metastatic brain disease caused by lung and breast cancer]. Zh Vopr Neirokhir Im N N Burdenko 2020;84(4):26–35.
Gállego Pérez-Larraya J, Hildebrand J. Brain metastases. Handb Clin Neurol 2014;121:1143–57.
Okada Y, Kobayashi M, Shinozaki M, Abe T, Kanemaki Y, Nakamura N, et al. Survival time and prognostic factors after whole-brain radiotherapy of brain metastases from of breast cancer. Acta Radiol Open 2020;9(7):2058460120938744.
Li Y, Wang S, Yang W, Liu H. Prognostic significance of molecular subtype, metastatic site and primary tumor surgery for survival in primary metastatic breast cancer: A SEER-based study. Medicine (Baltimore) 2021;100(27):e26619.
Khan M, Zhao Z, Arooj S, Zheng T, Liao G. Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:576926.
Bernhardt D, Adeberg S, Bozorgmehr F, Opfermann N, Hoerner-Rieber J, König L, et al. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. J Neurooncol 2017;134(1):205–12.
Murovic J, Ding V, Han SS, Adler JR, Chang SD. Impact of CyberKnife Radiosurgery on Median Overall Survival of Various Parameters in Patients with 1-12 Brain Metastases. Cureus 2017;9(12):e1926.
Peterson HE, Larson EW, Fairbanks RK, MacKay AR, Lamoreaux WT, Call JA, et al. Gamma knife treatment of brainstem metastases. Int J Mol Sci 2014;15(6):9748–61.
Additional Files
Published
Issue
Section
License
Copyright (c) 2023 Dawood Misbah, Muhammad Fawad-Ul-Qamar, Nadia Khaleeq, Alina Zaidi, Syed Zarak Ali Shah, Kashif Sajjad
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
